Bufalin/Huachansu / PARP Cancer Research Results

BF, Bufalin/Huachansu: Click to Expand ⟱
Features:
Bufalin/Huachansu is a component from Chinese toad venom. Bufalin is classified as a cardiac glycoside, specifically a type of bufadienolide.

Pathways:
-release of cytochrome c and subsequent activation of caspases
-enhance the expression of death receptors
-inhibit the PI3K/Akt/mTOR
-modulate the MAPK/ERK pathway
-inhibit NF-κB signaling
-induce cell cycle arrest at different checkpoints (commonly G0/G1 or G2/M)
-elevate intracellular ROS levels
-interfere with the Wnt/β-catenin signaling pathway
-modulate autophagy, a process that can either promote cell survival or lead to cell death
-Stabilization or activation of p53

Bufalin — Bufalin is a steroidal cardiotonic toxin and anticancer lead compound, classically isolated from toad venom (ChanSu / Huachansu) and belonging to the bufadienolide subclass of cardiac glycosides. It is commonly abbreviated BF. In cancer research, bufalin is best understood as a pleiotropic signaling disruptor whose most central pharmacology is linked to Na+/K+-ATPase engagement, with downstream effects on survival signaling, mitochondrial death pathways, redox stress, stemness, invasion, and therapy resistance.

Primary mechanisms (ranked):

  1. Na+/K+-ATPase targeting with disruption of pump-linked oncogenic signaling and, in some models, α1-subunit destabilization/degradation.
  2. Mitochondria-linked apoptosis with cytochrome c release, caspase activation, and loss of survival signaling.
  3. Suppression of PI3K/Akt/mTOR and related pro-survival nodes, with context-dependent effects on ERK, NF-κB, and STAT3-linked programs.
  4. ROS elevation with stress-kinase activation (especially JNK/p38) and redox-dependent death signaling; this is important but usually downstream/secondary rather than the first initiating event.
  5. Cell-cycle arrest and mitotic disruption, including Aurora kinase-related effects in some tumor models.
  6. Inhibition of stemness, EMT, migration, invasion, angiogenesis, and drug-resistance phenotypes, including Wnt/β-catenin- and YAP-associated programs in selected cancers.
  7. Autophagy modulation, which can be cytoprotective or cytotoxic depending on model and schedule.

Bioavailability / PK relevance: Translation is constrained by poor water solubility, low/variable bioavailability of bufadienolides, short apparent plasma persistence in human Huachansu infusion studies, and a narrow therapeutic window typical of cardiac glycosides. CYP3A-mediated metabolism and CYP3A4 inhibition/time-dependent inactivation raise drug-interaction concern. Delivery optimization by nanoparticles, prodrugs, and formulation engineering is mechanistically relevant, not merely cosmetic.

In-vitro vs systemic exposure relevance: Concentration-driven. Many mechanistic cancer studies report activity in low-nanomolar to submicromolar ranges, which is closer to plausibility than for many phytochemicals; however, human plasma bufalin levels reported during Huachansu infusion were only low ng/mL and showed little accumulation, so many higher in-vitro conditions likely exceed sustained clinically achieved free exposure. Any interpretation should therefore prioritize low-nanomolar findings and delivery-enabled tumor exposure rather than high-concentration cell-culture effects.

Clinical evidence status: Preclinical to small-human evidence only. There is substantial in-vitro and animal evidence, plus early Huachansu clinical studies in China and a phase I/II development path, but no convincing randomized evidence that bufalin-containing therapy improves major cancer outcomes. Current status is best described as experimental / adjunct-oriented rather than established anticancer therapy.

Mechanistic translation matrix

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Na+/K+-ATPase signalosome ↓ pump-linked oncogenic signaling; ↓ proliferation; apoptosis trigger ↓ ubiquitous pump function; cardiotoxicity risk P-R Upstream target engagement Most central mechanism. Bufalin behaves as a cardiac glycoside/bufadienolide with strong relevance to ATP1A1-linked signaling and tumor vulnerability, but normal-tissue exposure limits selectivity.
2 Mitochondria and intrinsic apoptosis ↑ cytochrome c release; ↑ caspases; ↑ mitochondrial dysfunction ↔ to ↓ tolerance window R-G Cell death induction Robust across many tumor models and commonly downstream of Na+/K+-ATPase disruption, ROS stress, and survival-pathway collapse.
3 PI3K Akt mTOR survival axis ↓ ↔ to ↓ R-G Anti-survival signaling One of the most repeatedly reported downstream axes. Often linked to apoptosis sensitization, growth arrest, and resistance reversal.
4 NF-κB inflammatory survival signaling ↓ ↔ to ↓ R-G Reduced survival and inflammatory tone Usually a secondary convergence node rather than the first molecular hit.
5 Mitochondrial ROS increase ↑ (dose-dependent) ↑ toxicity risk R Stress amplification Mechanistically important in several models, especially where JNK/p38 activation and autophagy-mediated death are observed. Not universal as the dominant initiating event.
6 JNK p38 stress kinase axis ↑ ↔ R-G Pro-apoptotic stress signaling Often coupled to ROS elevation and mitochondrial injury.
7 ERK MAPK signaling ↓ or ↔ (context-dependent) ↔ R-G Growth signaling modulation Reported direction varies by model; best treated as context-dependent rather than universally suppressed.
8 Cell-cycle and mitotic machinery ↑ G0/G1 or G2/M arrest; ↓ Aurora activation ↔ to ↓ proliferative tissues G Cytostasis and mitotic disruption Relevant in multiple cancers; checkpoint phenotype varies by model.
9 Wnt β-catenin stemness axis ↓ stemness; ↓ EMT; ↓ invasion ↔ G Anti-metastatic differentiation pressure Important in selected resistant and stem-like states rather than universally core.
10 Autophagy program ↑ or ↓ (context-dependent) ↔ R-G Death modulator Can either support survival or contribute to death. Interpretation must stay model-specific.
11 Chemosensitization and resistance reversal ↑ sensitivity ↔ G Adjunct potential Preclinical evidence is strong enough to keep this high in translational interest, but human confirmation is still weak.
12 Clinical Translation Constraint Exposure limited Systemic toxicity relevant G Therapeutic window constraint Poor solubility, formulation dependence, short plasma persistence, CYP3A liability, and cardiac-glycoside toxicity remain the main barriers to direct clinical deployment.

P: 0–30 min
R: 30 min–3 hr
G: >3 hr
PARP, poly ADP-ribose polymerase (PARP) cleavage: Click to Expand ⟱
Source:
Type:
Poly (ADP-ribose) polymerase (PARP) cleavage is a hallmark of caspase activation. PARP (Poly (ADP-ribose) polymerase) is a family of proteins involved in a variety of cellular processes, including DNA repair, genomic stability, and programmed cell death. PARP enzymes play a crucial role in repairing single-strand breaks in DNA.
PARP has gained significant attention, particularly in the treatment of certain types of tumors, such as those with BRCA1 or BRCA2 mutations. These mutations impair the cell's ability to repair double-strand breaks in DNA through homologous recombination. Cancer cells with these mutations can become reliant on PARP for survival, making them particularly sensitive to PARP inhibitors.
PARP inhibitors, such as olaparib, rucaparib, and niraparib, have been developed as targeted therapies for cancers associated with BRCA mutations.

PARP Family:
The poly (ADP-ribose) polymerases (PARPs) are a family of enzymes involved in a number of cellular processes, including DNA repair, genomic stability, and programmed cell death.
PARP1 is the predominant family member responsible for detecting DNA strand breaks and initiating repair processes, especially through base excision repair (BER).

PARP1 Overexpression:
In several cancer types—including breast, ovarian, prostate, and lung cancers—elevated PARP1 expression and/or activity has been reported.
High PARP1 expression in certain cancers has been associated with aggressive tumor behavior and resistance to therapies (especially those that induce DNA damage).
Increased PARP1 activity may correlate with poorer overall survival in tumors that rely on DNA repair for survival.
Scientific Papers found: Click to Expand⟱
5724- BF,    A Novel Bufalin Derivative Exhibited Stronger Apoptosis-Inducing Effect than Bufalin in A549 Lung Cancer Cells and Lower Acute Toxicity in Mice
- vitro+vivo, Lung, A549
Apoptosis↑, Casp3↑, cl‑PARP↑,
5725- BF,  TMZ,    Bufalin Induces Apoptosis and Improves the Sensitivity of Human Glioma Stem-Like Cells to Temozolamide
- in-vitro, GBM, NA
TumCG↓, TumCP↓, CSCs↓, cl‑Casp3↑, PARP↑, Telomerase↓, eff↑,
5726- BF,    Bufalin exerts antitumor effects in neuroblastoma via the induction of reactive oxygen species-mediated apoptosis by targeting the electron transport chain
- Review, neuroblastoma, SK-N-BE
Apoptosis↑, TumCP↓, TumCMig↓, MMP↓, ROS↑, ETC↓, Bcl-2↓, BAX↑, cl‑Casp3↑, cl‑PARP↑, eff↓, TumCG↓, Ki-67↓, PCNA↓,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

ETC↓, 1,   MMP↓, 1,  

Cell Death ⓘ

Apoptosis↑, 2,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,   cl‑Casp3↑, 2,   Telomerase↓, 1,  

DNA Damage & Repair ⓘ

PARP↑, 1,   cl‑PARP↑, 2,   PCNA↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 1,   TumCG↓, 2,  

Migration ⓘ

Ki-67↓, 1,   TumCMig↓, 1,   TumCP↓, 2,  

Drug Metabolism & Resistance ⓘ

eff↓, 1,   eff↑, 1,  

Clinical Biomarkers ⓘ

Ki-67↓, 1,  
Total Targets: 20

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: PARP, poly ADP-ribose polymerase (PARP) cleavage
3 Bufalin/Huachansu
1 temozolomide
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:49  Target#:239  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page